Home
Request Info
The Data is Public. The Risks Are Not.
Controlled trials test the ideal.
Real-world outcomes reveal the rest.

01:06

YouTube

RiskSignalData ai

RiskSignalData.ai is a next-generation, AI-powered veterinary drug safety platform. Built to serve pet owners, veterinarians, and industry stakeholders, it delivers real-time visibility into veterinary drug risks, powered by 40 years of FDA and global drug risk data. This is the first platform designed to bring transparency, accountability, and actionable intelligence to veterinary medicine, when it matters most. đź”— Explore the platform: https://risksignaldata.ai

01:10

YouTube

RiskSignalData: AI-Powered Oversight for Veterinary Drug Safety

RiskSignalData.ai is the first AI platform built to uncover safety concerns in veterinary drug use—leveraging decades of FDA and global adverse event data. Built for veterinarians, pet parents, insurers, regulators, lawyers, and investors, the platform delivers transparency and accountability in post-market veterinary medicine. Visit our website: RiskSignalData.ai © 2025 RiskSignalData.ai. All rights reserved.

Solving a Critical Market Gap
Pharmacovigilance tools are standard in human medicine, but veterinary healthcare lacks a comparable, unified infrastructure. RiskSignalData.ai transforms raw post-market adverse event data - reported by regulatory agencies worldwide - into actionable insights for veterinarians, animal owners, insurers, legal professionals, and financial stakeholders.
Detect Deviations - Not Just Risks
We go beyond traditional safety signal detection. RiskSignalData.ai systematically evaluates post-market outcomes to identify how and when real-world data differs meaningfully from the expected drug safety and efficacy parameters defined during drug approval. This is more than a query engine - it’s a novel framework for post-market falsifiability scoring, designed to track where claims may no longer align with observed field data.
Identify Emerging Patterns
Unexplained fatalities in healthy animals. Delayed recovery in patients that match trial criteria. Harmful outcomes when drugs assumed to be safe in combination are used together. These signals often remain hidden in post-market gray zones - overlooked by regulators until external pressure demands action, and avoided by manufacturers to protect commercial interests. We bring these patterns to light, closing critical gaps in transparency and accountability.
Falsifiability Engine
We transform pre-approval trial parameters into logical boundaries - including tested species, age, dosage, route of administration, and reported adverse events. We then compare post-market data against these boundaries to identify patterns that fall outside the original scope.
By making these deviations measurable, we provide a new framework for assessing where real-world outcomes may diverge from pre-market expectations - helping stakeholders surface insights that would otherwise remain hidden.
Validate Manufacturer Claims Over Time
Most veterinary drugs are approved based on brief, small-sample trials in narrow animal cohorts - typically young, healthy animals without comorbidities. In clinical practice, however, these drugs are administered across varied populations, species, and contexts that may fall outside the original trial scope.
RiskSignalData.ai supports longitudinal analysis to assess whether post-market outcomes remain consistent with pre-approval safety claims - helping preserve transparency, scientific continuity, and accountability throughout a product’s lifecycle.
Market Opportunity
70% of U.S. households have at least one pet. As the veterinary sector experiences unprecedented growth and consolidation, the demand for transparency and accountability in veterinary drug safety has never been more urgent.
$4B
U.S. Pet Health Insurance Market
Estimated premiums in 2024
$22B
U.S. Veterinary Pharmaceutical Market
Expected to reach by 2030
$60B
Private Equity Investment
Flowing into U.S. veterinary sector since 2017
$70B
U.S. Veterinary Service Market
Projected growth by 2030
$150B
U.S. Consumer Pet Spending
Total expenditure in 2024
Despite rapid consolidation and capital inflows, the veterinary industry still lacks a centralized system for post-market drug safety analysis. This creates blind spots for veterinarians, pet-owners, insurers, and investors - who must make decisions without longitudinal visibility into how drugs perform after approval.
RiskSignalData.ai addresses this gap by transforming fragmented adverse event data into structured intelligence - enabling early signal detection, trend validation, and defensible insights for every stakeholder.
Use of this site constitutes acceptance of our Terms of Use and Privacy Policy.
Made with